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Resumo
Os conhecimentos actuais da patologia molecular do 
cancro do pulmão requerem outra caracterização his-
tológica, para além de carcinoma de células pequenas 
e carcinoma não pequenas células para suporte da te-
rapia personalizada e entendimento do valor real dos 
fármacos actualmente disponíveis.
Como o diagnóstico e seguimento clínico da maioria 
dos casos de cancro do pulmão se baseia em produtos 
de biópsia e citologia, a classificação imunoistoquími-
ca do carcinoma broncopulmonar (IBPCC) é necessá-
ria para suporte morfológico da classificação da WHO 
1999/2004, clarificando as características celulares das 
neoplasias e o entendimento da carcinogénese.
Abstract
The current state of molecular knowledge on lung 
cancer demands a histological classification which 
goes beyond small-cell and non-small-cell carcinoma 
to provide support for tailored therapy in aiding in 
understanding of the drugs currently available. 
As diagnosis and follow-up in the vast majority of 
lung cancer cases is based on biopsies and cytology 
samples, Immunohistochemical Bronchial Pulmo-
nary Carcinoma Classification (IBPCC) is necessary 
to reveal the raft of characteristics available. This pro-
vides morphological support for the WHO’s 
1999/2004 classification, in addition to an under-
standing of carcinogenesis. 
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O painel imunoistoquímico reforça os tipos histoló-
gicos principais do carcinoma bronco – pulmonar: 
carcinoma epidermóide (queratinas de alto peso mo-
lecular – HWMC), carcinoma adenoscamoso (CK/
/TTF1, MWMC), carcinoma neuroendócrino (Chrg, 
Syn, CD56, TTF1, Ki67) e adenocarcinoma (CK7, 
Ck20, TTF1); as variantes do carcinoma de células 
grandes e do carcinoma sarcomatóide são englobados 
num único grupo de carcinomas pleomórficos (CK7, 
TTF1, HWMC, VMT, desmina, actina), onde cabe 
o polimorfismo e o pleomorfismo celular.
A quimioterapia do carcinoma broncopulmonar con-
tinuará baseada no platino e na gemcitabina no futu-
ro próximo e a IBPCC será uma ferramenta simples e 
eficiente para o registo das características e tipos his-
tológicos do carcinoma do pulmão presentes nas bi-
ópsias e amostras citológicas para suporte da evidên-
cia clínica e dos ensaios farmacêuticos.
Rev Port Pneumol 2009; XV (6): 1101-1119
Palavras-chave: Carcinoma broncopulmonar, imu-
noistoquímica.
The immunohistochemical panel clarifies the main 
morphology and cytology characteristics to maintain 
the leading histological types as squamous cell carci-
noma (high weight molecular cytokeratins/HWMC), 
adenosquamous carcinoma (CK7, TTF1, HWMA), 
neuroendocrine carcinoma (Chrg, Syn, CD56, 
TTF1, Ki67), adenocarcinoma (CK7, CK20, TTF1) 
and bring the polymorphic and pleomorphic carci-
nomas under a single banner of pleomorphic carci-
noma (Ck7, TTF1, HWMC, VMT, Desmin, Actin) 
which shelters large cell carcinomas and sarcomatoid 
carcinomas.
Lung cancer chemotherapy will still be based on plat-
inum and gemcitabine for the near future and the 
IBPCC is a simple and efficient tool for streamlining 
the registration of lung cancer histological character-
istics in biopsies and other reduced samples to sup-
port clinical evidence and trials.
Rev Port Pneumol 2009; XV (6): 1101-1119
Key-words: Bronchial-pulmonary carcinoma, im-
munohistochemistry.
Introduction
Pathology is far from what it can be consi-
dered as to have been its beginning in the 
XVIII century by the first descriptions of 
Morgagni and further by Virchow with the 
use of the microscope. What is important 
to have in mind is the fact that the survival 
age was in the thirties years of age, even 
from the time of Hippocrates, Celsius and 
Galen. The Egyptians left their papyrus, 
namely Ebers´ (Amenhotep Kingdom 
1557 – 1501BC) with exhaustive reports 
of infections and tumours, although be-
nign, but related to the different parts of 
the body. Medicine began at Cos School in 
Greece (500BC), from where the Corpus 
Hipocra ticus emanated, followed by the 
De Artibus of Aulus Cornelius Celsius 
from Verona – Italy. The Arabs had the 
possibility to ensemble the two knowledges 
while divagating around the Mediterra-
nean during their struggles, making then a 
wealthy synthesis gathering also the Per-
sian and Indian know ledge. Kanum is re-
ally a joint canon made then by Ibis Sina/
Avicena (980-1037). By then confidence 
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was achieved in recogni zing malignant tu-
mours and metastasizing1.
The actual known scientific method comes in 
the catholic/medieval time with Galileo 
(1564-1634) and Kepler (1571-1635), suc-
ceeding Copernicus (1473) and having as 
starting point the greec-italian-arab-indu 
knowledge since the Salerno School (XI cen-
tury). The Magister Salernus as we get to 
know today was probably written by a Jew, an 
Arab, a Greek and a Christian. The Tumori-
bus Praeter Naturum written by Gabriel Falo-
pius (1523-1562) is the first pathology book 
and the microscope used by Malpighi (1562-
1682) helped in rooting the anatomy bases. 
Histology encased in between by the eyes of 
Bichat (1771-1802) together with anatomy 
and pathology, reinforced by René Laennec 
(1781-1826). The expertise of Rudolf Vir-
chow (1821-1826) with an acromatic micros-
cope (1830) brought the zell/cell to the medi-
cal practice1-3.
This way we get to the contemporary medi-
cine we can consider to have its beginning 
in 1953 with the DNA double helix of Wat-
son and Creek and in fifty years we jumped 
into the molecular pathology and modern 
medicine with a huge advance in disease 
therapy, gathering all technical methodolo-
gies now available. At this point is the de-
manding diagnosis of bronco-pulmonary 
carcinoma made on small biopsies (or a 
couple of cells) submitted to the WHO 
1999/2004 classification4-5.
We owe to the Sweden doctor Leiv Kreyberg 
the first histological characterization of bron-
chial-pulmonary carcinomas done in 1954 
after studying carbon mines workers. These 
patients exhibited the illnesses dependent on 
mines environment: carbon lung and silicosis 
together with tuberculosis and developing 
lung cancer very frequently. Smoking accele-
rated the incidence of lung cancer as we know 
today. In 1967, the Organisation Mondiale 
de la Santé supported the first work directed 
to the standardization of tumoural nomen-
clature adapted to each organ to discipline 
Pathologists that frequently renamed diffe-
rently the same lesion. Types Histologiques 
des Tumeurs du Poumon was the blue book 
number 1 of the WHO blue book series di-
rected to the histological classifications of 
neoplasias in each organ2,6.
The incidence of lung cancer is far from di-
minishing its incidence although the habit 
of smoking is clearly decreasing and still 60 
to 70% of new lung cancer cases are diag-
nosed in non surgical stages with 10 to 12 
months probability of survival. This situa-
tion and the poverty of survival rates 
achieved with the possible therapy conduct-
ing to a high mortality raised the general 
histological reference of small cell carcino-
ma and non small cell carcinoma in Patho-
logists´ reports as the first histological type 
meant non surgical behaviour because of 
very poor prognosis compared with the other 
types. As molecular pathology is developing 
towards predictive therapy which means 
personalized choice dependent on carcino-
ma histological type and quite defined par-
ticularities, the diagnosis has to be made 
with approximate precision in the small 
biopsies obtained by endobronchial exami-
nation, transthoracic biopsies and even in 
groups of small number of neoplastic cells 
of cytological methods7-10.
The use of immunohistochemial antibodies 
and the experience acquired in reporting lung 
cancer in surgical specimens based in total in-
clusion in paraffin of tumours, have conduct-
ing either to WHO classification and to the 
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recognition of the possible different patterns 
of bronchial-pulmonary carcinomas that can 
be explored in small biopsies11,12.
Lung cancer classifications 
till WHO 1999/2004
The morphological descriptions of lung car-
cinomas have been refined since Kreyberg 
and the OMS/1967 classification with 
maintenance of the histological types, firstly 
described in five groups, revealing a large 
heterogeneity recognized ab initio:
1. adenocarcinomas and epidermoid epithe-
liomas;
2. carcinoids;
3. solid tumours with or without mucus 
and giant cell and clear cell epitheliomas;
4. Small cell anaplastic epitheliomas and 
subtypes (and mixed tumours where 
combined carcinomas and neuroendo-
crine large cell tumours were reported);
5. Non-classifiable tumours neither by pat-
tern nor by cell type.
The following reorganizations of criteria re-
ported in 1976 and 1981 preserved the ini-
tial nomenclature and the OMS/1981 writ-
ten in French reports the actual histological 
types for malignant epithelial pulmonary 
tumours:
Epidermoid carcinoma
Small cell carcinoma
Adenocarcinoma
Large cell carcinoma
Adenosquamous carcinoma
Carcinoid
Bronchial glands carcinoma
In a special group – IV. Tumeurs Divers – 
carcinosarcoma and pulmonary blastoma 
were recognized. Spindle cell carcinoma and 
other neuroendocrine tumours were inclu-
ded in the groups of epidermoid carcinoma 
and small cell carcinoma respectively6.
The WHO 1999/2004 classifications main-
tained the same histological groups and ba-
sic knowledge in genetics was added to the 
new Blue Book format of the in English 
written WHO editions5.
Beyond establishing criteria for recognition 
of patterns and histological types, the actual 
classification has also commitment with 
prognosis and predictive studies of molecu-
lar pathology have definitely shown a corre-
lation between morphology and prognosis 
outcome directing the choice of therapy13,14.
As the available molecular studies can not 
be forgotten when reporting small biopsies 
and cytological smears, the morphological 
criteria have to be applied as sharply as pos-
sible to neoplastic cells to be reliable and 
exclusive as this tumoural representation is 
kept in 60 to 70% of cases in non-surgical 
stages at the time of diagnosis, when therapy 
has to be decided15.
Small cell carcinomas, epidermoid carcino-
mas and adenocarcinomas offer no prob-
lems to be classified even in cases where dif-
ferential diagnosis between primary and 
secondary adenocarcinomas has to be. The 
last situation is reasonably solved by apply-
ing morphological criteria and the currently 
used immunohistochemical antibodies CK 
20 (digestive adenocarcinomas) and CK7 
and TTF1 (pulmonary adenocarcinomas).
Meanwhile the recognition of more variants 
to be included in the WHO recognised 
groups reinforce the need of recurring to 
embryology and cellular type knowledge to 
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decide rigorous classification and differen-
tial diagnosis.
Still in the actual classification, repetitions 
of cellular types under different histological 
types and the recognition of large cells, 
giant cells, spindle cells and inflammatory 
cells in small biopsies raise the utility of a 
new future classification with synthesis of 
language and grouping.
Differentiating histological types in 
biopsies by immunohistochemistry
Squamous cell carcinoma
The variants of epidermoid carcinoma 
actua lly recognized include papillary, clear 
cell, small cell and basaloid morphologies. 
Only the first one can be recognized in small 
biopsies without the use of immunohis-
tochemistry (IHC) when clear basal mem-
brane invasion is obvious together with the 
well differentiated pattern with extensive 
keratinisation16.
The other patterns and poorly differentiated 
epidermoid carcinoma – not exhibiting ke-
ratinisation and justifying the title of epi-
dermoid carcinoma instead of squamous 
cell carcinoma – require use of IHC17,18.
High-weight-molecular cytokeratins (HWMC 
– LP34/34βE12/…) are of daily use as ade-
nocarcinomas of the bronchus or of the lung 
do not express those keratins that are ex-
pressed by metaplastic pavimentoid cells in 
respiratory epithelium, where normally a 
clear basal cell positive layer is distinctly de-
fined till the epithelium of the bronchioles 
where it is absent (Fig. 1).
Also TTF1 (Thyroid Transcription Factor 
1) and CK7 are consistently negative in epi-
dermoid carcinomas and if positive, the he-
terogeneity of cell types has to be considered 
and reported to make the diagnosis of com-
bined small cell carcinoma or ade-
nosquamous carcinoma and then validate 
therapy and prognosis19.
The basaloid variant can only be reported as 
a pattern if no keratinisation is present as 
the basaloid carcinoma included in the large 
cell carcinoma group has poorer prognosis. 
CK7 may be expressed together with 
HWMC in these carcinomas and their ra-
rity has also to be kept in mind.
Small cell variant of epidermoid carcinoma 
has become easily recognisable when TTF1 
and Ki67 proliferation marker are searched 
together with HWMC. A Ki67 prolifera-
tion index higher than 80% together with 
clear expression of HWMC indicates a 
combined small cell carcinoma and epider-
moid carcinoma; TTF1 may show the same 
quantity of nuclear expression or lower in 
this situation.
The WHO classification does not embrace 
the cellular capacities determined by IHC 
in small pieces of tissue as it has been done 
considering surgical specimens where poor-
Fig. 1 – High weight molecular cytokeratins in basal bron-
chial cells. Mixed type adenocarcinoma. 34βE12 X 200
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ly differentiated areas of carcinomas were 
not considered to be reported and not ex-
plored as it would have made a much more 
complex classification – the 10% law20.
Adenocarcinoma
Heterogeneity of primary bronchial-pulmo-
nary adenocarcinomas and also of sarcoma-
toid and large cell carcinomas of the lung is 
related to embryology and multiple bron-
chial – pulmonary cell types with different 
functions are now under the explanation of 
the epithelial mesenchimal transition 
(EMT) theory21.
As referred for squamous cell carcinoma, 
HWMCs delineate the basal cell bronchial 
layer till bronchioles where ciliated cells 
continue to express CK7 and alveolar cells, 
CK7 and TTF1 focally. Cell types vary from 
cuboidal to columnar, with either variable 
mucinous cytoplasm and basal or hobnail 
nuclei22-24.
The expression of CK20 by adenocarcino-
mas has to be related with the common em-
bryological origin of upper and lower airways 
together with anterior intestine as it does not 
occur in mature respiratory epithelium. 
These primary carcinomas when expressing 
CK7 without TTF1, define intestinal carci-
nomas and having histogenetical dependence 
from respiratory epithelium might well be 
called bronchial adenocarcinomas25,26.
The histogenesis of bronchial-pulmonary 
adenocarcinomas has long taken the atten-
tion of Pathologists and Researchers as first-
ly mature cells were not supposed to give 
origin to malignant cells in respiratory epi-
thelium where epidermoid carcinoma de-
velops from epidermoid metaplasia and 
small cell carcinoma, from one or various 
types of related cells with neuroendocrine 
variable expression not yet clearly defined 
beyond the high proliferation rate27,28.
Meanwhile bronchial and bronchiolar pre-
invasive lesions can be demonstrated for 
ade nocarcinoma as: basal cell hyperplasia, 
papillary hiperplasia, papillary metaplasia 
and bronchiolar columnar cell dysplasia 
(BCCD) (Fig. 2)29,30.
A B C
Fig. 2 – Bronchial preinvasive lesions: basal cell hyperplasia HE X 100; papillary hyperplasia CK20 X 100; papillary meta-
plasia HE X 100
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Noguchi (Cancer 1995) called attention for 
small adenocarcinomas while in Europe still 
large tumours were diagnosed. Those small 
adenocarcinomas are of mixed type, with or 
without predominance of bronchioloalveolar 
(BAC) non-mucinous pattern with different 
prognosis, better when predominant non-mu-
cinous BAC is present. Neoplastic cells express 
CK7 and TTF1, independently of the present 
patterns, even when concerning a pure acinar 
or papillary adenocarcinoma, this histological 
type long known to have the poorest progno-
sis among adenocarcinomas31-33.
Terminal respiratory unit adenocarcinoma 
described by Noguchi do not overtake 3cm 
diameter, has central desmoplastic stroma 
with tumoural acinar pattern, surrounded 
by papillary, micropapillary, acinar or non-
mucinous BAC, keeping fidelity to CK7 
and TTF1 nuclear expression and negativity 
to the other IHC markers (Fig. 3)34-35.
The above referred theory is extended to 
larger adenocarcinomas where less orga-
nized patterns are present and then the 
TTF1 nuclear expression may be lost while 
CK7 is constant and this event has to be 
taken as very important when reporting 
bio psies as the less differentiated patterns 
determine a poorer prognosis and are often 
gathered in lymphatic vessels of bronchial 
biopsies36,37.
Differential diagnosis with mesothelioma 
keeps being a challenge when clinicians for-
get to refer pleural expansion without the 
presence of a definite mass and after report-
ing adenocarcinoma CAT does not show 
the tumour. The classical pseudo-mesothe-
liomatous adenocarcinoma has become rare. 
Nowadays calretinin keeps being the most 
reliable antibody for malignant mesothelial 
cells together with cytokeratins (CK5/6 or 
CK7) to mark spindle mesotheliomatous 
cells. The use of anti-glicoproteins antibo-
dies as CEA and Ber-EP4 is needed to dis-
card adenocarcinoma and cytoplasmic 
membrane reinforcement by EMA in ma-
lignant mesothelial cells is reliable38-41.
BAC keeps being controversial as consi-
dered an in situ carcinoma in WHO classi-
fication and then reported with metastases 
in some series. Nonetheless atypical ade-
nomatous hyperplasia is the preinvasive le-
sion of non-mucinous type that is also the 
pattern found in mixed type adenocarcino-
ma while pure mucinous BAC is multifocal 
and often bilateral. The mixed non-muci-
nous and mucinous type is seen in larger le-
sions when desmoplastic reaction is present 
with acinar invasion and then related to 
lymph node metastases. This last situation 
is no more a BAC in WHO classification 
but a mixed type adenocarcinoma42.
The IHC expression of BAC is also variable 
as limited to CK7 and TTF1 in non-muci-
nous type and revealing CK20 and scarcity 
of CK7 and no TTF1 in some cases of mu-
cinous BAC. This IHC pattern can be re-
lated to an intestinal mucinous BAC that 
can be multifocal and distinct from bron-
chial adenocarcinoma (Fig. 4)43.
No descriptions are available till now to dis-
tinguish gender patterns and it is well stated 
that pulmonary adenocarcinomas in wom-
en have a better prognosis. The feminine 
adenocarcinomas may show particular pat-
terns as hepatoid pattern and oestrogen, 
progesterone and variable cytoplasmic 
membrane glicoproteins IHC expression. 
When in small biopies an endometrioid 
pattern is suggested (Fig. 5).
The immunohistochemical patterns of ade-
nocarcinomas raise the possibility of defi-
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A B
C D
E F
Fig. 3 – Terminal respiratory unit adenocarcinoma. A: central desmoplasia; B: true papillae; C: micropapillae; D: acinar pat-
tern; E – F: peripheral acinar and papillary growth
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C D
E F
Fig. 4 – Bronchial adenocarcinoma – A: positive CK20 in malignant cells, not expressed in respiratory epithelium; B: CK 
34βE12 in current basal cells; C: CK7 revealing microacinar pattern (TTF1-). BAC – mucinous type – D: TTF1 -; E: intestinal 
glandular type; F: CK20 scarce positivity (CK7+)
Reclassificação do carcinoma broncopulmonar: diferenciação do tipo histológico 
em biópsias por imuno-histoquímica
Lina Carvalho
R e v i s t a  P o r t u g u e s a  d e  P n e u m o l o g i a1110
Vol XV  N.º 6  Novembro/Dezembro  2009
ning a classification as si mple as the catego-
ries of IHC antibodies expressed, assumed 
in a small panel useful to define the plat-
form for predictive therapy44-48.
Neuroendocrine tumours
Depending on patient age different small 
cell tumours raise differential diagnosis 
solved by IHC and complementary analysis 
to distinguish from small cell carcinoma. 
For this histological type, after nuclear 
crushing artefact, Ki67 proliferation index 
is the most reliable marker revealing more 
than 80% positive malignant nuclei. The 
alveolar cell maker TTF1 is also expressed 
by these tumours but not consistently. 
While chromogranin and synaptophisin ex-
pression are constant in carcinoids, CD56 is 
more prone to small cell carcinoma49,50.
Small cell carcinoma is keratin tempera-
mental varying the expression from null till 
high expression of HWMC or CK7. In 
these cases a combined small cell carcinoma 
and squamous cell carcinoma or adenocar-
cinoma has to be taken in mind in small 
biopsies and careful attention given to bron-
chial epithelium that may reveal also posi-
tive TTF1 and Ki 67 dysplasia (Fig. 6)51,52.
Neuroendocrine carcinomas in the lung 
concern typical and atypical carcinoids and 
large cell neuroendocrine carcinoma beyond 
small cell carcinoma and histological crite-
ria are clearly defined in the WHO 2004 
classification. It is important to recognize 
typical carcinoid lymph node metastases as 
this may occur till 14% of the cases53,54.
The thyroid transcription factor 1 was also 
found in type II pneumocytes and connects 
an adenocarcinoma to the lung but also 
characterizes small cell carcinoma. Usually 
carcinoids do not express that factor that 
has also been understood as a proliferation 
marker. The proliferation index validated 
by Ki67 in small and artefactual biopsies is 
mandatory to distinguish typical and atypi-
cal carcinoid (<4-10%), large cell neuroen-
docrine carcinoma (20-50%) and small cell 
carcinoma (>80%) together with neuroen-
docrine markers usually55,56.
Adenosquamous carcinoma
Not many concern has been given to this 
pulmonary carcinoma but in small biopsies 
it is common to have HWMC and CK7 ex-
pression in neoplastic cells. When carefully 
observed it is possible to see in the pave-
mentous/epidermoid cellular clusterings, 
luminal drafts with both different expres-
sion and patterns of those cytokeratins.
This way adenosquamous carcinoma may 
present in a spectrum from a well differen-
tiated type to moderately differentiated and 
poorly differentiated types keeping the ex-
pression of CK7 and HWMC in separate 
and/or in the same cells, with combined 
patterns. Usually TTF1 is absent but if pre-
Fig. 5 – Adenocarcinoma - «endometrioid» acinar pattern. 
Female 62 years old; peripheral left lower lobe tumour 
(CAT) and bone metastases. HE X 100
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sent the cell type has to be considered to 
raise the possibility of a combined small cell 
or a TRU adenosquamous carcinoma, de-
pending on Ki67 nuclear rate57.
It has to be kept in mind that salivary gland 
tumours have epidermoid and glandular 
patterns that are not mistaken for ade-
nosquamous carcinomas. Also the cam5.2 
marker and androgen and oestrogen recep-
tors are expressed in those tumours.
Pleomorphic carcinomas
The confidence in IHC to classify bronchial 
– pulmonary carcinomas is defined in Ta-
ble I (empty spaces mean negativity) based 
in the WHO 2004 classification. Then large 
cell carcinomas and sarcomatoid carcino-
mas have to be joined under the designation 
of pleomorphic carcinomas because of three 
reasons: the present approach is a result of 
working mostly in biopsies beyond surgical 
specimens; pleomorphism (different cell 
types) and polymorphism (one cell type 
with various forms) interface each other in 
the two groups of large cell and sarcomatoid 
carcinomas; lastly and to reinforce the two 
mentioned reasons, large cells and clear cells 
are seen everywhere in the previous histo-
logical types and need IHC (and mucinous 
stains PAS and Alcian blue) to allocate 
them.
The bronchial-pulmonary carcinoma grou-
ping is designed in Tabel II where mor-
phology and adequate IHC panel are en-
sembled in order to be used in cytology, 
biopsies and surgical specimens reporting. 
The utility of this classification can be tes-
ted in a biopsy of a poorly differentiated 
squamous cell carcinoma exhibiting large 
cells that keep expressing only HWMC 
confirming that grading carcinomas is not 
important. Also, as large cells may repre-
sent pleomorphic adenocarcinomas, only 
CK7 expression is expected; on the other 
hand, the expression of CK7 and HWMC 
toge ther point to poorly differentiated ad-
enosquamous carcinoma. The TTF1 nu-
clear positive staining keeps a good marker 
to recognize pulmonary carcinomas with 
varia ble patterns.
It is important to verify that the columnar 
and/or cuboidal cells of an adenocarcinoma 
component in a pleomorphic carcinoma 
also express vimentin in an irregular way. 
This may be important to recognize prog-
Fig. 6 – Combined small cell carcinoma and adenocarcinoma – A: neuroendocrine epithelial dysplasia; B: CK7 revealing acinar pattern; C: Ki67 100% 
positive malignant nuclei and characterizing neuroendocrine epithelial dysplasia (arrow)
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nosis and histogenesis in future. By now, 
vimentin, desmin and smooth muscle actin 
have to be expressed (one positive antibody 
is sufficient) to define a pleomorphic carci-
noma independently of the observed histo-
logical patterns58.
Discussion
The Pathologist concern is beyond the diag-
nosis of non-small cell or small cell carcino-
ma when reporting small biopsies or cytolo-
gy specimens and IHC became an easy and 
useful tool. Cell morphology and histologi-
cal types and patterns are leaders of report-
ing and rationalize the choice of limited 
IHC panel. This concern goes further than 
diagnosis as important therapeutic drugs are 
revealing prognostic value based in bronchial 
and pulmonary carcinoma histology59-62.
The IHC panel defined in Table I and quo-
ted in the proposed immunohistochemical 
Table I – Bronchial – Pulmonary carcinoma: Histological typing and immunohistochemistry
Ck7
Ck20
CDX2
MUC2
TTF1
34βE12
LP34
p63
VMT
Desmin
Actin    
CD56
Synapto Chromog Ki67
SQC +
SCC +/- + >90%
ADC Bronchial/intestinal + + +/-
Mixed + +
Acinar & BAC / TRU + +
Papillary + +
BAC mucinous + +/- +/-
     Nonmucinous + +
     Mixed + +/- +/-
Solid carcinoma + +/- +/-
LCC LCNEC + + + 50-80%
Other variants + +/- +/- +/-
ADSQ Well differentiated + +/- +
Moderately differentiated + +/- +
Poorly differentiated + +
Sarcom Pleomorphic ADC + + +/-
                     SQC + + +/-
                     SCC + +/- +/- +
               LCNEC + +/- +/- +
Spindle Cell C + + +
Giant Cell C + +/- +
Carcinosarcoma + + +
Carcinoid Typical / atypical +/- -/+ +/- + <10%
SQC – squamous cell carcinoma SCC – small cell carcinoma    
ADC – adenocarcinoma  BAC – bronchioloalveolar carcinoma
TRU – terminal respiratory unit LCC – large cell carcinoma
LCNEC – large cell neuroendocrine carcinoma ADSC – adenosquamous carcinoma
C – carcinoma   VMT – vimentin
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bronchial-pulmonary carcinoma grouping/
/classification – IBPCC – in Table II is 
widely used as the applied antibodies are re-
liable and easily validated. The usefulness of 
the presenting IBPCC relies in its simplicity 
of understanding cell types and cellular po-
tentialities either in bronchial cylindrical 
and ciliated epithelium and also in carcino-
mas arising in the TRU unit or when pre-
senting as solid tumours of heterogeneous 
patterns and cellularity. This work may be a 
refining of the attempt made by Dr Edwards 
in 1987 when ICM was not so accessible63.
The IBPCC raises from the knowledge ac-
quired in reporting surgical specimens after 
observing loads of slides of the whole sec-
tioned tumour. An adenocarcinoma of the 
lung does not express HWMC and even in 
the hilum where intestinal adenocarcinomas 
develop more frequently, CK20 and CK 7 are 
exclusive with a variability of the nuclear pre-
sence of TTF1. Also when acinar and/or pap-
illary paterns are present in a small biopsy the 
expression of TTF1 and CK20 persist in the 
surgical specimen where complementing pat-
terns of a mixed adenocarcinoma show up.
BAC is a challenging group of tumours 
whose macroscopy and histology has not 
yet been definitely corroborated. The muci-
nous type expressing CK20 and non-muci-
nous type with hobnail and Clara cells ex-
pressing CK7 and TTF1, with mixed types 
in between, as prone intestinal type with 
mucinous papillae or as gathering CK20, 
CK7 and TTF1 expression, have different 
therapeutical, staging and prognostic ef-
fects. The first group known to be multifo-
cal and with bilateral potentiality and the 
other types more often an unique mass, 
with or without central desmoplasia, defy 
the WHO criteria.
The above supposed purity changes when 
HWMC or other markers need to be inclu-
ded according with morphology beyond 
well differentiated squamous cell carcino-
ma. When neoplastic cells express CK7 
uniformly and TTF1 and HWMC in clus-
ters, adenosquamous carcinoma is a correct 
diagnosis. Signet ring cells can be seen in 
this context. Whether scales or prickles are 
absent squamous cell carcinoma keeps be-
ing well characterized by expressing only 
HWMC.
Differential diagnosis of lymphoma, PNET, 
synovial sarcoma … have to be taken in ac-
count when dealing with small cell tumours 
and consider small cell carcinoma in the 
group of pulmonary neuroendocrine carci-
nomas leaving tumorlets behind as a prein-
vasive lesion in the development of carci-
noid. Again TTF1 plays an important role 
together with Ki67 as proliferation predic-
tors in small cell carcinoma and large cell 
neuroendocrine carcinoma. Some small cell 
carcinomas present with lnger survival and 
still no explanation is adequate. It is fantasy 
admit that these cases might be poorly com-
bined small cell carcinomas where CK7 and 
HWMC are expressed at cellular level with-
out pertinent patterns as understood for 
ade nosquamous carcinomas64,65.
The mesenchimal antibodies more often 
used are vimentin, actin and desmin that 
are not expressed in adenocarcinomas, neu-
roendocrine carcinomas and epidermoid 
differentiating carcinomas. Better than con-
sidering two independent groups of large 
cell carcinoma and sarcomatoid carcinoma, 
still subdivided, or quote them together as 
poorly differentiated carcinomas, an unique 
group of pleomorphic carcinoma (Table II) 
shows to be either comprehensive and fea-
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Table II – Bronchial-pulmonary carcinoma – Immunohistochemical classifi cation
Squamous cell carcinoma – HWMC
Variants: papillary; clear cell; small cell; basaloid
Adenosquamous carcinoma – CK7/ TTF1/HWMC
Variants: well, moderately, poorly differentiated
Neuroendocrine carcinoma – chromogranin/synaptophisin/CD56/TTF1/ Ki67
Histological types: Carcinoid – typical / atypical
  Small cell carcinoma / Combined
  Large cell neuroendocrine carcinoma / Combined
Adenocarcinoma – CK7/TTF1/CK20
Histological types: Acinar adenocarcinoma
  Papillary adenocarcinoma
  Mixed Acinar / BAC - TRU
  Mixed adenocarcinoma
  Intestinal adenocarcinoma
  Intestinal bronchioloalveolar carcinoma
  Pulmonary bronchioalveolar carcinoma
  Mixed bronchioloalveolar carcinoma 
  Mucinous carcinoma and Cystadenocarcinoma
  Feminine adenocarcinoma
Pleomorphic carcinoma – CK7/TTF1/HWMC/VMT/Desmin/Actin
Histological types: Pleomorphic squamous cell carcinoma 
  Pleomorphic adenocarcinoma
  Clear cell adenocarcinoma
  Solid adenocarcinoma with or without mucin production
  Fetal adenocarcinoma
  Signet ring cell carcinoma
  Basaloid carcinoma
  Lymphoepitelioma-like carcinoma
  Large cell carcinoma with rabdoid phenotype
  Spindle cell carcinoma
  Giant cell carcinoma
  Carcinosarcoma
  Pulmonary blastoma 
Salivary gland tumours
  Mucoepidermoid carcinoma
  Adenoid cystic carcinoma
  Epithelial-myoepithelial carcinoma
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sible as IHC is rationalized to cover all the 
listed histological types.
Grouping these carcinomas as poorly diffe-
rentiated carcinomas might be minimalist 
as in these rare histological types may reside 
knowledge concerned with histogenesis and 
allowing the understanding of the actual 
theories of carcinogenesis meaning specific 
differentiation.
Pathologists fight with understanding where 
and why started a metaplasia or dysplasia to 
help in Preventive Medicine. In bronchial 
– pulmonary carcinoma some architectural 
alterations are coming to attention and be-
ing reported to help clinicians to follow pa-
tients with more expertise. In Table III a 
potential group of preinvasive lesions is re-
cognized and data has to be gathered to re-
cognize them in small biopsies.
Embriogenesis may conduct our research to 
understand polarized epithelial phenotype 
together with highly motile mesenchimal 
phenotype as is observed in pleomorphic 
carcinomas, together when carcinomatous 
patterns are evident or independently by re-
cognizing solid or sarcomatoid patterns that 
should not be called poorly differentiated. 
This understanding can be again translated 
to cellular level and revealed by immunohis-
tochemistry. Two good examples for illus-
trating this spectrum are lymphoepitelioma-
like carcinoma and solid adenocarcinoma. 
The first case might be considered a poorly 
differentiated squamous cell carcinoma be-
cause there is HWMC cellular expression 
and is known to have a better prognosis than 
the other histolical subtypes included in the 
large cell carcinoma. The second example 
fluctuates between a solid adenocarcinoma 
with mucin production and solid adenocar-
cinoma expressing TTF1 focally beside dis-
crete large cells or small spindle cells with 
cytoplasmic vimentin39.
At the bottom of the group carcinosarcoma 
and blastoma polarize epithelial to me-
senchimal transiton theory for carcinogen-
esis and embryogenesis potentiality respec-
tively. Spindle cell and giant cell patterns 
reinforce the cellular level capacities and the 
IBPCC already discussed67,68.
The IBPCC is a useful tool as molecular pa-
thology is coming to the pathologist bench 
demanding accurate morphology recogni-
tion based in small tissue or cell samples de-
pendent on an IHC panel that has to be 
reported having in mind reliable prognosis 
outcome69,70.
Predictive therapy is already a reality in 
some pulmonary pathology centres and it 
is a result of trials that gather therapy, gene 
expression and/or mutations and progno-
sis. Still the commoner applied language is 
small cell carcinoma and non-small cell 
carcinoma with already cellular morpho-
logical and immunohistochemical bias. In 
the application and distinction between 
clinical outcomes from the applied thera-
pies, first and second lines, a second bio-
psy may become mandatory to revalidate 
cellular characteristics to predict therapy 
answer39, 71, 72.
Still an enormous effort has to be done in 
order to understand the multidirectionality 
importance of each morphological pattern 
in each histological type of lung cancer 
when observing surgical specimens by des-
cending to molecular level. After this labo-
rious task more knowledge will be brought to 
cellular level characterization when diagnos-
ing in small samples or neoplastic cells73-76.
The complementary or primordial ap-
proach may reside in the neoplastic cells 
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Table III – Bronchial-pulmonary pre-invasive lesions
Squamous metaplastic carcinoma in situ
Basal cell hyperplasia with atypia
Bronchial papillary hyperplasia
Bronchial papillary metaplasia
Neuroendocrine dysplasia
Tumorlet
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia
Bronchiolar columnar cell dysplasia
Atypical adenomatous hyperplasia
entourage concerning immune cells and 
mesenchymal cells wondering for stem 
cells and predictive therapy for these tar-
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